This book reviews the application of Nanobiotechnology in the development of Nanomedicine, while also discussing the latest trends and challenges in the clinical translation of Nanomedicine. Nanomedicine refers to the application of Nanotechnology to medicine and holds tremendous potential for achieving improved efficiency, bioavailability, dose response, personalized medicine and enhanced safety as compared to conventional medicines. The book first introduces readers to the basic concepts of Nanomedicine, and to technological advances in and applications of Nanotechnology in treatment,…mehr
This book reviews the application of Nanobiotechnology in the development of Nanomedicine, while also discussing the latest trends and challenges in the clinical translation of Nanomedicine. Nanomedicine refers to the application of Nanotechnology to medicine and holds tremendous potential for achieving improved efficiency, bioavailability, dose response, personalized medicine and enhanced safety as compared to conventional medicines.
The book first introduces readers to the basic concepts of Nanomedicine, and to technological advances in and applications of Nanotechnology in treatment, diagnosis, monitoring, and drug delivery. In turn, it reviews the current status of multi-functionalization strategies for using Nanoparticles in the targeted delivery of therapeutic agents. The book's third and final section focuses on the regulatory and safety challenges posed by Nanomedicine, including industry and regulatory agencies' efforts to address them.
Malay K Das (MPharm, PhD) is a Professor of Pharmaceutics at the Department of Pharmaceutical Sciences, Dibrugarh University, India. His research interests include Novel Drug Delivery Systems, Pharmaceutical Nanotechnology, Nanomedicine, and Transdermal and Targeted Drug Delivery Systems. He has handled several major research projects sponsored by the DST, DBT, ICMR, UGC and AICTE. Professor Das has been honored with the prestigious DBT-Biotechnology Overseas Associateship at the University of South Florida, Tampa, USA and the DST-UKIERI Research Award in collaboration with the Institute of Pharmaceutical Sciences, King¿s College, London. He has several publications to his credit, including peer-reviewed research and review articles in various international journals of repute, and chapters in various books for international publishers. Yashwant V Pathak (MPharm, Executive MBA, MSCM, PhD) is a Professor and the Associate Dean for Faculty Affairs at the Taneja College of Pharmacy, University of South Florida, Tampa. He received his PhD from Nagpur University in India and subsequently his EMBA and MSCM (Conflict Management) from Sullivan University in Louisville, KY, USA. His extensive experience in industry and academia spans over 42 years. He has authored more than 200 publications, including peer-reviewed research papers, review articles and book chapters. In addition, he has edited more than 30 books in the areas of Nanotechnology, Drug Delivery Systems, and Nutraceuticals. He is the recipient of many international awards, including two Fulbright Fellowships. In addition to serving as series editor for Nutraceuticals: Basic Research and Clinical Applications, published by CRC Press, Dr Pathak is an Adjunct Professor at the Faculty of Pharmacy, Airlangga University, Indonesia.
Inhaltsangabe
Chapter 1_Applications of Nano Biotechnology in the development of Nano Medicine.- Chapter 1.1. Nano biotechnology and its application in Nano medicine:An Overview.- Chapter 1.2. Nano biotechnology for therapeutic targeting of circulating tumor cells in the blood.-Chapter 1.3. Application of Nano biotechnology in clinical diagnosis.- Chapter 1.4. Anti-diabetic Nano formulation from herbal source.- Chapter 1.5. Nano materials for alternative antibiotic therapy.- Chapter 2. Nano Medicine: concept, development, clinical applications and evidences.- Chapter 2.1. Nano medicines and Nanodelivery systems: trends and perspectives.- Chapter 2.2. Nano medicines in drug delivery from synthetic/natural sources to their clinical applications.- Chapter 2.3. Nano medicines: Products on the market and in the pipeline.- Chapter 2.4. Transdermal Nano medicines for enhanced dose control and tissue targeting.- Chapter 2.5. Multifunctional mesoporous silica nanoparticles for biomedical applications.- Chapter 2.6. Advances in pulmonary Nano medicine for therapeutic management of respiratory diseases.- Chapter 2.7. Functionalized lipid-polymer hybrid nanoparticles for cancer targeted chemotherapy.- Chapter 2.8. Lipid-polymer hybrid nanoparticle based Nano medicine for enhanced management of psoriasis.- Chapter 2.9. Nano medicines for gene therapy.- Chapter 2.10. Herbal Nano medicines for cancer chemotherapy.- Chapter 2.11. pH-responsive nanomaterials for cancer diagnosis and treatment.- Chapter 2.12. Stimuli-responsive polymers for cancer Nano medicines.- Chapter 2.13. Nano medicine for challenging cancers such as pancreas and other relatively inaccessible organs.- Chapter 2.14. Targeting Nano medicines to bone metastasis and cancer stem cells.- Chapter 2.15. Clinical impact of Nano sized extracellular vesicles for theranostic areas of Nanomedicines.- Chapter 2.16. Multifunctional Nano scale particles for theranostic application in healthcare.- Chapter 2.17. Ligand nanoparticle conjugation approach for targeted cancer chemotherapy.- Chapter 3. Regulatory, safety and marketing aspects of Nano Medicine.- Chapter 3.1. Nano toxicity and risk-benefit assessment of Nano medicines.- Chapter 3.2. Risk assessment and risk management guidance of Nano medicines in
occupational safety and health.- Chapter 3.3. Clinical toxicities of Nano medicines.- Chapter 3.4. Public health concerns related to Nano medicines.- Chapter 3.5. Wait and watch: Regulatory approaches to Nano medicines.- Chapter 3.6. Global growth of Nano medicines and what role it will play for economically weak countries.
Chapter 1_Applications of Nano Biotechnology in the development of Nano Medicine .- Chapter 1.1. Nano biotechnology and its application in Nano medicine:An Overview.- Chapter 1.2. Nano biotechnology for therapeutic targeting of circulating tumor cells in the blood.-Chapter 1.3. Application of Nano biotechnology in clinical diagnosis.- Chapter 1.4. Anti-diabetic Nano formulation from herbal source.- Chapter 1.5. Nano materials for alternative antibiotic therapy.- Chapter 2. Nano Medicine: concept, development, clinical applications and evidences.- Chapter 2.1. Nano medicines and Nanodelivery systems: trends and perspectives.- Chapter 2.2. Nano medicines in drug delivery from synthetic/natural sources to their clinical applications.- Chapter 2.3. Nano medicines: Products on the market and in the pipeline.- Chapter 2.4. Transdermal Nano medicines for enhanced dose control and tissue targeting.- Chapter 2.5. Multifunctional mesoporous silica nanoparticles for biomedical applications.- Chapter 2.6. Advances in pulmonary Nano medicine for therapeutic management of respiratory diseases.- Chapter 2.7. Functionalized lipid-polymer hybrid nanoparticles for cancer targeted chemotherapy.- Chapter 2.8. Lipid-polymer hybrid nanoparticle based Nano medicine for enhanced management of psoriasis.- Chapter 2.9. Nano medicines for gene therapy.- Chapter 2.10. Herbal Nano medicines for cancer chemotherapy.- Chapter 2.11. pH-responsive nanomaterials for cancer diagnosis and treatment.- Chapter 2.12. Stimuli-responsive polymers for cancer Nano medicines.- Chapter 2.13. Nano medicine for challenging cancers such as pancreas and other relatively inaccessible organs.- Chapter 2.14. Targeting Nano medicines to bone metastasis and cancer stem cells.- Chapter 2.15. Clinical impact of Nano sized extracellular vesicles for theranostic areas of Nanomedicines.- Chapter 2.16. Multifunctional Nano scale particles for theranostic application in healthcare.- Chapter 2.17. Ligand nanoparticle conjugation approach for targeted cancer chemotherapy.- Chapter 3. Regulatory, safety and marketing aspects of Nano Medicine.- Chapter 3.1. Nano toxicity and risk-benefit assessment of Nano medicines.- Chapter 3.2. Risk assessment and risk management guidance of Nano medicines in
occupational safety and health.- Chapter 3.3. Clinical toxicities of Nano medicines.- Chapter 3.4. Public health concerns related to Nano medicines.- Chapter 3.5. Wait and watch: Regulatory approaches to Nano medicines.- Chapter 3.6. Global growth of Nano medicines and what role it will play for economically weak countries.
Chapter 1_Applications of Nano Biotechnology in the development of Nano Medicine.- Chapter 1.1. Nano biotechnology and its application in Nano medicine:An Overview.- Chapter 1.2. Nano biotechnology for therapeutic targeting of circulating tumor cells in the blood.-Chapter 1.3. Application of Nano biotechnology in clinical diagnosis.- Chapter 1.4. Anti-diabetic Nano formulation from herbal source.- Chapter 1.5. Nano materials for alternative antibiotic therapy.- Chapter 2. Nano Medicine: concept, development, clinical applications and evidences.- Chapter 2.1. Nano medicines and Nanodelivery systems: trends and perspectives.- Chapter 2.2. Nano medicines in drug delivery from synthetic/natural sources to their clinical applications.- Chapter 2.3. Nano medicines: Products on the market and in the pipeline.- Chapter 2.4. Transdermal Nano medicines for enhanced dose control and tissue targeting.- Chapter 2.5. Multifunctional mesoporous silica nanoparticles for biomedical applications.- Chapter 2.6. Advances in pulmonary Nano medicine for therapeutic management of respiratory diseases.- Chapter 2.7. Functionalized lipid-polymer hybrid nanoparticles for cancer targeted chemotherapy.- Chapter 2.8. Lipid-polymer hybrid nanoparticle based Nano medicine for enhanced management of psoriasis.- Chapter 2.9. Nano medicines for gene therapy.- Chapter 2.10. Herbal Nano medicines for cancer chemotherapy.- Chapter 2.11. pH-responsive nanomaterials for cancer diagnosis and treatment.- Chapter 2.12. Stimuli-responsive polymers for cancer Nano medicines.- Chapter 2.13. Nano medicine for challenging cancers such as pancreas and other relatively inaccessible organs.- Chapter 2.14. Targeting Nano medicines to bone metastasis and cancer stem cells.- Chapter 2.15. Clinical impact of Nano sized extracellular vesicles for theranostic areas of Nanomedicines.- Chapter 2.16. Multifunctional Nano scale particles for theranostic application in healthcare.- Chapter 2.17. Ligand nanoparticle conjugation approach for targeted cancer chemotherapy.- Chapter 3. Regulatory, safety and marketing aspects of Nano Medicine.- Chapter 3.1. Nano toxicity and risk-benefit assessment of Nano medicines.- Chapter 3.2. Risk assessment and risk management guidance of Nano medicines in
occupational safety and health.- Chapter 3.3. Clinical toxicities of Nano medicines.- Chapter 3.4. Public health concerns related to Nano medicines.- Chapter 3.5. Wait and watch: Regulatory approaches to Nano medicines.- Chapter 3.6. Global growth of Nano medicines and what role it will play for economically weak countries.
Chapter 1_Applications of Nano Biotechnology in the development of Nano Medicine .- Chapter 1.1. Nano biotechnology and its application in Nano medicine:An Overview.- Chapter 1.2. Nano biotechnology for therapeutic targeting of circulating tumor cells in the blood.-Chapter 1.3. Application of Nano biotechnology in clinical diagnosis.- Chapter 1.4. Anti-diabetic Nano formulation from herbal source.- Chapter 1.5. Nano materials for alternative antibiotic therapy.- Chapter 2. Nano Medicine: concept, development, clinical applications and evidences.- Chapter 2.1. Nano medicines and Nanodelivery systems: trends and perspectives.- Chapter 2.2. Nano medicines in drug delivery from synthetic/natural sources to their clinical applications.- Chapter 2.3. Nano medicines: Products on the market and in the pipeline.- Chapter 2.4. Transdermal Nano medicines for enhanced dose control and tissue targeting.- Chapter 2.5. Multifunctional mesoporous silica nanoparticles for biomedical applications.- Chapter 2.6. Advances in pulmonary Nano medicine for therapeutic management of respiratory diseases.- Chapter 2.7. Functionalized lipid-polymer hybrid nanoparticles for cancer targeted chemotherapy.- Chapter 2.8. Lipid-polymer hybrid nanoparticle based Nano medicine for enhanced management of psoriasis.- Chapter 2.9. Nano medicines for gene therapy.- Chapter 2.10. Herbal Nano medicines for cancer chemotherapy.- Chapter 2.11. pH-responsive nanomaterials for cancer diagnosis and treatment.- Chapter 2.12. Stimuli-responsive polymers for cancer Nano medicines.- Chapter 2.13. Nano medicine for challenging cancers such as pancreas and other relatively inaccessible organs.- Chapter 2.14. Targeting Nano medicines to bone metastasis and cancer stem cells.- Chapter 2.15. Clinical impact of Nano sized extracellular vesicles for theranostic areas of Nanomedicines.- Chapter 2.16. Multifunctional Nano scale particles for theranostic application in healthcare.- Chapter 2.17. Ligand nanoparticle conjugation approach for targeted cancer chemotherapy.- Chapter 3. Regulatory, safety and marketing aspects of Nano Medicine.- Chapter 3.1. Nano toxicity and risk-benefit assessment of Nano medicines.- Chapter 3.2. Risk assessment and risk management guidance of Nano medicines in
occupational safety and health.- Chapter 3.3. Clinical toxicities of Nano medicines.- Chapter 3.4. Public health concerns related to Nano medicines.- Chapter 3.5. Wait and watch: Regulatory approaches to Nano medicines.- Chapter 3.6. Global growth of Nano medicines and what role it will play for economically weak countries.
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Shop der buecher.de GmbH & Co. KG Bürgermeister-Wegele-Str. 12, 86167 Augsburg Amtsgericht Augsburg HRA 13309